Highlights CombiGene AB

Equities

COMBI

SE0016101935

Delayed Nasdaq Stockholm Other stock markets 15:20:30 28/06/2024 BST			5-day change	1st Jan Change
3.02 ^SEK	-1.31%		-3.82%	+12.27%

06-24	CombiGene Enters into A License Agreement with Spark for the Epilepsy Project CG01	CI
05-27	CombiGene Appoints New Chief Scientific Officer	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CombiGene Enters into A License Agreement with Spark for the Epilepsy Project CG01	06-24	CI
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-17	CI
CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries	03-13	CI
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	02-20	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-16	CI
CombiGene AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
CombiGene Taps Charles River Laboratories as Clinical Research Partner for Pain Project	11-01	MT
Combigene AB Chooses Charles River as Preclinical Toxicology Partner for COZY01 Pain Project	31/10/23	CI
CombiGene AB and Zyneyro Choose Initial Indication in the Cozy01 Pain Project	26/10/23	CI
Spark Therapeutics Terminates Collaboration Agreement for the Epilepsy Project CG01 with CombiGene AB	14/10/23	CI
CombiGene AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	25/08/23	CI
Combigene AB to Play an Integrate Part in the Development of National Infrastructure for ATMPs	24/05/23	CI
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
CombiGene AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	17/02/23	CI
Combigene Enters into Collaboration Agreement with Zyneyro for the Development of A Unique Concept for Effective Relief of Chronic Pain	09/01/23	CI
CombiGene AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/11/22	CI
CombiGene AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	25/08/22	CI
CombiGene AB Reports Earnings Results for the First Quarter Ended March 31, 2022	12/05/22	CI
CombiGene AB Signs Agreement with A Potential Value of USD 328.5 Million with Spark Therapeutics	21/02/22	CI
CombiGene AB Reports Earnings Results for the Full Year Ended December 31, 2021	17/02/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CombiGene AB

Equities

COMBI

SE0016101935

Highlights

Filters